"In the DIG trial, published in 1997, digoxin had a neutral effect on the primary endpoint of mortality, but a 28% reduction in heart failure hospitalizations (a secondary endpoint) was observed.

Please provide your email address to receive an email when new articles are posted on . Digitalis glycosides, such as digoxin, may prevent worsening HF events in patients with LVEF of 50% or less.

Placebo-controlled evidence across 9013 patients showed a lower composite risk (HR 0.85) driven by reduced worsening HF events rather than any detectable mortality benefit. Worsening HF events were ...

Wearable device data could predict New York Heart Association functional class similarly to clinical measures and six-minute walk test. HealthDay News — For patients with atrial fibrillation, digoxin ...

Heart drugs called digitalis glycosides, which include digoxin and digitoxin, have been used for centuries, but their place in the modern treatment of heart failure remains undefined. Results were ...